Alnylam initiates U.S. application for lumasiran for PH1

Alnylam Pharmaceuticals (NASDAQ:ALNY) initiates its rolling New Drug Application (NDA) in the U.S. for lumasiran for the treatment of primary hyperoxaluria type 1 (PH1). Specifically, it has submitted the non-clinical components. It expects to complete the filing this quarter.

https://seekingalpha.com/news/3531070-alnylam-launches-u-s-application-for-lumasiran-for-ph1